EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN 200MG/245 MG TBL FLM 30X1 II
What is the maximum co-payment for EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN?
If the insurance company contributes, the maximum co-payment is 4 411,51 Kč. The maximum pharmacy price is 4 788,35 Kč. A pharmacy may provide the medicine for a lower price, but not for a higher price.
Does the medicine have reimbursement from public health insurance?
A medicine whose use is, in the public interest, appropriate to concentrate in specialized facilities pursuant to Section 15(10) of the Public Health Insurance Act. The medicine is reimbursed as ZÚLP and only from a facility that has a contract with the health insurer.
Does EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN have a counted co-payment set?
No, this medicine has no counted co-payment.
How much does the insurance company pay for one dispensed reimbursed pack?
376,84 Kč.
Does the insurance company pay a higher amount in some cases?
No, the medicine has no increased reimbursement.
Does the medicine have an indication restriction?
Is it available without a medical prescription?
No, the medicine cannot be obtained without a prescription.
Which medical specialist may prescribe EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN?
Prescription is not conditional on a medical specialization.
What is the composition of EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN?
Emtricitabin (200 mg), tenofovir-disoproxil-maleinát, tenofovir-disoproxil (245 mg), neznámá látka s kódem 3755, neznámá látka s kódem 4873, červený oxid železitý, koloidní bezvodý oxid křemičitý, monohydrát laktosy, magnesium-stearát, hypromelosa, oxid titaničitý, neznámá látka s kódem 4105, neznámá látka s kódem 12184, žlutý oxid železitý. More information about the composition can be found in the SPC, section 6.1.
Where can I find information about correct use of the medicine?
Which medicines are similar to EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN?
The medicine belongs to ATC group J05AR03 – TENOFOVIR-DISOPROXIL A EMTRICITABIN. Medicines with the same active substance can be found here.
Who manufactures EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN?
Mylan Pharmaceuticals Limited, Dublin (IRL)
Is the medicine in shortage?
The latest report from the manufacturer is from 27. 1. 2026. Production was terminated with effect from 27. 1. 2026. The manufacturer lists medicines with the following code as a potential substitute:
What is the unique code for EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN?
The medicine has code 0271773. Code details can be found here.
How many packs of EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN were previously dispensed on prescriptions in Czechia?
Show prescription medicine consumption
How many packs of EMTRICITABINE/TENOFOVIR DISOPROXIL MYLAN were previously dispensed on request forms in Czechia?
PODOBNÉ PŘÍPRAVKY:
The page was last updated on 28. 02. 2026